Cargando…

Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration

Sirtuin 2 (SIRT2) is a protein deacylase enzyme that removes acetyl groups and longer chain acyl groups from post-translationally modified lysine residues. It affects diverse biological functions in the cell and has been considered a drug target in relation to both neurodegenerative diseases and can...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Alexander L., Rajabi, Nima, Kudo, Norio, Lundø, Kathrine, Moreno-Yruela, Carlos, Bæk, Michael, Fontenas, Martin, Lucidi, Alessia, Madsen, Andreas S., Yoshida, Minoru, Olsen, Christian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341974/
https://www.ncbi.nlm.nih.gov/pubmed/34458803
http://dx.doi.org/10.1039/d0cb00036a
_version_ 1783733991829929984
author Nielsen, Alexander L.
Rajabi, Nima
Kudo, Norio
Lundø, Kathrine
Moreno-Yruela, Carlos
Bæk, Michael
Fontenas, Martin
Lucidi, Alessia
Madsen, Andreas S.
Yoshida, Minoru
Olsen, Christian A.
author_facet Nielsen, Alexander L.
Rajabi, Nima
Kudo, Norio
Lundø, Kathrine
Moreno-Yruela, Carlos
Bæk, Michael
Fontenas, Martin
Lucidi, Alessia
Madsen, Andreas S.
Yoshida, Minoru
Olsen, Christian A.
author_sort Nielsen, Alexander L.
collection PubMed
description Sirtuin 2 (SIRT2) is a protein deacylase enzyme that removes acetyl groups and longer chain acyl groups from post-translationally modified lysine residues. It affects diverse biological functions in the cell and has been considered a drug target in relation to both neurodegenerative diseases and cancer. Therefore, access to well-characterized and robust tool compounds is essential for the continued investigation of the complex functions of this enzyme. Here, we report a collection of chemical probes that are potent, selective, stable in serum, water-soluble, and inhibit SIRT2-mediated deacetylation and demyristoylation in cells. Compared to the current landscape of SIRT2 inhibitors, this is a unique ensemble of features built into a single compound. We expect the developed chemotypes to find broad application in the interrogation of SIRT2 functions in both healthy and diseased cells, and to provide a foundation for the development of future therapeutics.
format Online
Article
Text
id pubmed-8341974
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-83419742021-08-26 Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration Nielsen, Alexander L. Rajabi, Nima Kudo, Norio Lundø, Kathrine Moreno-Yruela, Carlos Bæk, Michael Fontenas, Martin Lucidi, Alessia Madsen, Andreas S. Yoshida, Minoru Olsen, Christian A. RSC Chem Biol Chemistry Sirtuin 2 (SIRT2) is a protein deacylase enzyme that removes acetyl groups and longer chain acyl groups from post-translationally modified lysine residues. It affects diverse biological functions in the cell and has been considered a drug target in relation to both neurodegenerative diseases and cancer. Therefore, access to well-characterized and robust tool compounds is essential for the continued investigation of the complex functions of this enzyme. Here, we report a collection of chemical probes that are potent, selective, stable in serum, water-soluble, and inhibit SIRT2-mediated deacetylation and demyristoylation in cells. Compared to the current landscape of SIRT2 inhibitors, this is a unique ensemble of features built into a single compound. We expect the developed chemotypes to find broad application in the interrogation of SIRT2 functions in both healthy and diseased cells, and to provide a foundation for the development of future therapeutics. RSC 2021-01-14 /pmc/articles/PMC8341974/ /pubmed/34458803 http://dx.doi.org/10.1039/d0cb00036a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Nielsen, Alexander L.
Rajabi, Nima
Kudo, Norio
Lundø, Kathrine
Moreno-Yruela, Carlos
Bæk, Michael
Fontenas, Martin
Lucidi, Alessia
Madsen, Andreas S.
Yoshida, Minoru
Olsen, Christian A.
Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
title Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
title_full Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
title_fullStr Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
title_full_unstemmed Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
title_short Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
title_sort mechanism-based inhibitors of sirt2: structure–activity relationship, x-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341974/
https://www.ncbi.nlm.nih.gov/pubmed/34458803
http://dx.doi.org/10.1039/d0cb00036a
work_keys_str_mv AT nielsenalexanderl mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT rajabinima mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT kudonorio mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT lundøkathrine mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT morenoyruelacarlos mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT bækmichael mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT fontenasmartin mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT lucidialessia mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT madsenandreass mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT yoshidaminoru mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration
AT olsenchristiana mechanismbasedinhibitorsofsirt2structureactivityrelationshipxraystructurestargetengagementregulationofatubulinacetylationandinhibitionofbreastcancercellmigration